1. Olson, J. D. College of American Pathologists Consensus Conference XXXVI: Diagnostic Issues in Thrombophilia. Arch. Pathol. Lab. Med. 126:1277-1279, 2002.

2. Khoury, M. J., McCabe L. L., and McCabe E. R. B. Genomic medicine: population screening in the age of genomic medicine. N. Engl. J. Med. 348(1):50-58, 2003.

3. Mann, K. G. Biochemistry and physiology of blood coagulation. Thromb. Haemost. 82:165-174,1999.

4. Brandt, J. T. Overview of hemostasis, in Clinical Laboratory Medicine, McClatchey, K. D., ed., Lippincott Williams & Wilkins, Philadlephia, PA, 2002, pp. 988-1009.

5. de Groot, P. G. The role of von Willebrand factor in platelet function. Sem in Thromb. Hemost. 28:133-138, 2002.

6. Morrissey, J. H. Tissue factor and factor VII initiation of coagulation, in Hemostasis and Thrombosis, Colman, R. W., Hirsh, J., Marder, V. J., Clowes, A. W.,and George, J. N. ed., Lippincott Williams and Wilkins, Philadelphia, PA, 2001, pp. 89-101.

7. Esmon, C. T. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J. Biol. Chem. 264:4743-4746, 1989.

8. Collen, D. The plasminogen (fibrinolytic) system. Thromb. Haemost. 82:259-270, 1999.

9. Tefferi, A., Wieben, E., Dewald, G. W., Whiteman, D. A. H., Bernard, M. E., and Spelsberg, T. C. Primer on medical genomics: Part II: Background principles and methods on molecular genetics. Mayo Clin. Proc. 77:785-808, 2002.

10. Rennert, H. and Leonard, D. G. B. Basic principles of molecular biology, in Diagnostic Molecular Pathology, W. B. Saunders, Philadelphia, PA, 2003, pp. 25-51.

11. Reitsma, P. H. Genetic Principles underlying disorders of procoagulant and anticoagulant proteins, in Hemostasis and Thrombosis, Colman, R. W., Hirsh, J., Marder, V. J., Clowes, A. W., and George, J. N. ed., Lippincott Williams and Wilkins, Philadelphia, PA, 2001, pp. 59-87.

12. Lane, D. A. and Grant, P. J. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 95:1517-1532, 2000.

13. Kottke-Marchant, K. Genetic polymorphisms associated with venous and arterial thrombosis. Arch. Pathol. Lab. Med. 126:295-304, 2002.

14. Franco, R. F. Gene polymorphism of the haemostatic system and the risk of arterial thrombotic disease. Br. J. Haematol. 115:491-506, 2001.

15. Bertina, R. M. Molecular risk factors for thrombosis. Thromb. Haemost. 82:601-609, 1999.

16. Humphries, S. E., Panahloo, A., Montgomery, H.E., Green, F., and Yudkin, J. Gene-environment interaction in the determination of levels of haemostatic levels involved in thrombosis and fibrinolysis. Thromb. Hemost. 78:457-461, 1997.

17. Seligsohn, U. and Zivelin, A. Thrombophilia as a multigenic disorder. Thromb. Haemost. 98:297-301, 1997

18. Rosendaal, F. R. Venous thrombosis: a multicausal disease. Lancet 353:1167,1999.

19. Ridker, P. M., Miletich, J. P., Hennekens, C. H., and Buring, J. E. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 277:1305-1307, 1997.

20. Marlar, R. A. and Neumann, A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin. Thromb. Haemost. 16:299-310, 1990.

21. Tuddenham, E. G. D., Schwaab, R., Seehafer, J., et al. Haemophilia A : database of nucleotide substitutions, deletions, insertions, and rearrangements of the factor VIII gene, second edition. Nucleic Acids Res. 22:4861-4868, 1994.

22. Kazazian, H. H., Wong, C., Youssoufian, H., Scott, A. F., Phillips, D. G., and Antonarakis, S. E. Haemophilia A resulting from de novo insertion of L1 sequences represents a novel mechanism for mutation in man. Nature 332:164-166, 1998.

23. Fijnvandraat, K., Turenhout, E. A., van den Brink, E. N., et al. The missense mutation Arg503^Cys is related to antibody formation in a patient with mild hemophilia A. Blood 89: 4371-4377, 1997.

24. Gianelli, F., Green P. M., Sommer, S. S., et al. Haemophilia B: database of point mutations and short addition and deletions-eighth edition. Nucleic Acid Res. 26:265-268, 1998.

25. Briet, E., Bertina, R. M., van Tilberg, N. H., and Veltkamp, J. J., Haemophilia B Leiden: a sex linked hereditary disorder that improves after puberty. N. Engl. J. Med. 306:788-790, 1982.

26. Oldenberg, J., Quenzel, E. M., Harbrecht, U., et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br. J. Haematol. 98:240-244, 1997.

27. Nichols W. C., and Ginsburg, D. Von Willebrand disease. Medicine 76:1-20, 1997.

28. Schneppenheim, R., Budde, U., and Ruggeri, Z. M. A molecular approach to the classification of von Willebrand disease. Baillieres Clin. Haematol. 14:281-298, 2001.

29. Cooper, D. N., Millar, D. S., Wacey, A., et al. Inherited factor VII deficiency: molecular genetics and pathophysiology. Thromb. Hemost. 78:151-160, 1997.

30. Cooper, D. N., Millar, D. S., Wacey, A., et al. Inherited factor X deficiency: molecular genetics and pathophysiology. Thromb. Hemost. 78:161-172, 1997.

31. Asakai, R., Chung, D. W., Davie, E. W., and Seligsohn, U. Factor XI deficiency in Ashkenasi Jews in Israel. N. Engl. J. Med. 326: 153-158, 1996.

32. Schloesser, M., Zeerleder, S., Lutze, G., et al. Mutations in the human factor XII gene. Blood 90:3967-3977, 1997.

33. Anwar, R. and Miloszewski, K. J. Factor XIII deficiency. Br. J. Haematol. 107:468-484, 1999.

34. Cunningham, M. T., Brandt, J. T., Laposata, M., and Olson, J. D. Laboratory diagnosis of dysfibrinogenemia. Arch. Pathol. Lab. Med. 126:499-505, 2002.

35. Dahlbach, B., Carlsson, M., and Svensson, P. J., Familial throm-bophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc. Natl. Acad. Sci. USA 90:1004-1008,1993.

36. Bertina, R. M., Koeleman, B. P., Koster, T., et al. Mutation in blood coagulation factor V associated with resistance of activated protein C. Nature 369:64-67, 1994.

37. Williamson, D., Brown, K., Luddington R., Baglin, C., and Baglin, T. Factor V Cambridge, a new mutation (arg306-Thro) associated with resistance of activated Protein C. Blood 91:1140-1144, 1998.

38. Chan, W. P., Lee, C. K., Kwong, Y. L., et al. A novel mutation of Arg 306 of factor V gene in Hong Kong Chinese. Blood 91:1135-1139, 1998.

39. de Visser, M. C. H., Rosendaal, F. R., and Bertina, R. M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 93:1271, 1999.

40. Bernardi, F., Faioni, E. M., Castoldi, E., Castaman, G., Sacchi, E., and Mannucci, P. M. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 90:1552-1557, 1997.

41. Alhenc-Gelas, M., Nicaud, V., Gandrille, S., et al. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb. Haemost. 81:193, 1999.

42. Poort, S. R., Rosendaal, F. R., Reitsma, P. H., and Bertina, R. M. A common genetic variation in the 3-untranslated region of the pro-thrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 88:3698-3703, 1996.

43. Gehring, N. H., Frede, U., New-Yilik, G., et al. Increased efficiency of mRNA 3end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat. Genet. 28:389-392, 2001.

44. Egeberg, O. Inherited antithrombin deficiency causing throm-bophilia. Thromb. Diath. Haemorrh. 12:516-530, 1965.

45. Finazzi, G., Caccia, R., and Barbui, T. Different prevalences of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb. Haemost. 58:1094, 1987.

46. Reitsma, P. H., Bernardi, F., Doig, R. G., et al. Protein C deficiency: a database of mutations, 1995 update. On behalf of the subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH (1991). Thromb. Hemost. 73:876-889, 1995.

47. Gandrille, S., Borgel, D., Ireland, H., et al. Protein S deficiency: a database of mutations. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Hemostasis. Thromb. Haemost. 77:1201-1214, 1997.

48. Ploos van Amstel, J. K., van der Zanden, A. L., Bakker, E., Reitsma, P. H., and Bertina, R. M. Two genes homologues with human protein S cDNA are located on chromosome 3. Thromb. Haemost. 58:982-987, 1987.

49. Ohlin, A. K., Norlund, L., and Marlar, R. A. Thrombomoduliin gene variations and thromboembolic disease. Thromb. Haemost. 78:396-400, 1997.

50. Van der Velden, P. A., Krommenhoek-Van Es, T., Alaart , C. F., Bertina, R. M., and Reitsma, P. H. A frequent thrombomodulin amino acid dimorphism is not associated with thrombophilia. Thromb. Haemost. 65:511-513, 1991.

51. Rosendaal, F. R., High levels of VIII and venous thrombosis. Thromb. Haemost. 83:1-2, 2000.

52. Nigel, S. K. and McGlennen, R. C. Hyperhomocysteinemia and thrombophilia. Arch. Pathol. Lab. Med. 126:1367-1375, 2002.

53. Froost, P., Blom, H. J., Milos, R., et al. A candidate genetic risk factor for vascular disease. A common mutation in methylenetetrahy-drofolate reductase. Nat Genet. 10:111-113, 1995.

54. Hanson, N. Q., Aras, O., Yang, F., and Tsai, M. Y. C677T and A1298C polymorphisms of the methylenetetrahydofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post methionine load homocysteine in vascular disease. Clin. Chem. 47:661-666, 2001.

55. Lutz, C. T., Foster, P. A., Noll, W. W., et al. Multicenter evaluation of PCR methods for the detection of Factor V Leiden (R506Q) genotypes. Clini Chem. 44:1356-1357, 1998.

56. Rennert, H. and Leonard, D. G. B. Molecular methods in the diagnostic laboratory, in Diagnostic Molecular Pathology, Leonard, D. G. B., ed., W. B. Saunders, Philadelphia, PA, 2003, pp. 25-51.

57. Gomez, E., van der Poel, S., Jansen, J. H., van der Reijden, B. A., and Lowenberg, B. Rapid simultaeous screening of Factor V Leiden and G20210A prothrombin variant by multiplex polymerase chain reaction on whole blood. Blood 91:2208-2209, 1998.

58. Hezard, N., Cornillet-Lefebvre, P., Gillot, L., Potron, G., and Nguyen, P. Multiplex ASA PCR for a simultaneous detection of factor V Leiden gene, G-A 20210 prothrombin gene and C-T MTHFR gene mutations. Thromb. Haemost. 79:1054-1055, 1998.

59. Endler, G., Kyrle, P. A., Eichinger, S., Exner, M., and Mannhatler, C. Multiplex mutagenically separated PCR: simultaneous single tube detection of the factor V R506Q (G1691A), the prothrombin G20210A, and the methylenetetrahydrofolate reductaseA223V (C677T) variants. Clin. Chem. 47:333-335, 2001.

60. Kirschbaum, N. E. and Foster, P. A. The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance. Thromb. Haemost. 74:874-878, 1995.

61. van Ahsen, N., Shutz, E., Armstrong, V.W. and Oellerich, M. Rapid detection of prothrombotic mutations of prothrombin (G20210A), factor V (G1691 A), and methylenetetrahydrofolate reductase (c677T) by real-time fluorescence PCR with the LightCycler. Clin. Chem. 45:694-696, 1999.

62. Weidenhammer, E. M., Kahl, B. F., Wang, L., et al. Multiplexed, targeted gene expression profiling and genetic analysis on electronic microarrays. Clin. Chem. 48:1873-1882, 2002.

63. Kwiatkowski, R. W., Lyamichev, V., de Arruda, M., and Neri, B. Clinical, genetic, and pharmacogenetic applications of the Invader assay. Mol. Diagn. 4:354-364, 1999.

64. McGlennen, R. C. and Key, N. S. Clinical and laboratory management of the prothrombin G20210 mutation. Arch. Pathol. Lab. Med. 26:1319-1325, 2002.

65. Miesfeld, R. L. Contemporary applied molecular genetics, in Applied Molecular Genetics, Miesfeld, R. L., ed., Wiley-Liss, New York, 1999, pp. 237-265.

66. Wallace, R. W. DNA on a chip: serving up the genome for diagnostics and research. Mole. Med. Today 3:384-389, 1997.

67. Schrijver, I., Lay, M. J., and Zehnder, M.D. Diagnostic single nucleotide polymorphism analysis of Factor V Leiden and pro-thrombin 20210G>A. Am. J. Clin. Pathol. 119:490-496, 2003.

68. Press, R., Bauer, K., Kujovich, J. L., and Heit, J. A. Clinical utility of Factor V Leiden R506Q testing for the diagnosis and management of thromboembolic disorders. Arch. Pathol. Lab. Med. 126:1304-1318, 2002.

69. Graf, L., Welsh, C. H., Qamar, Z., Marlar, R. A. Activated Protein C Resistance Assay detects thrombotic risk factors other than factor V Leiden. Am. J. Clin. Pathol. 119:522-60.

70. Legnani, C. C., Palareti, G., Biagi, R., et al. Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of factor V Leiden mutation. Br. J. Hematol. 93:694-699, 1996.

71. Dahlbach, B. New molecular insights intp the genetics of throm-bophilia: resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb. Haemost. 74:139-148.

72. Heit, J. A., Silverstein, M. D., Mohr, D. N., et al. The epidemiology of venous thormobemboliism in the community Thromb. Haemost. 86:452-463, 2001.

73. Ridker, P. M., Hennekens, C. H., Lindpaintner,K., Stampfer, M. J., Eisenberg, P. R., and Miletich, J. P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N. Engl. J. Med. 332:912-917, 1995.

74. Burke, W. Genomic medicine: genetic testing. N. Engl. J. Med. 347: 1867-1875, 2002.

75. Martinelli, I., Mannucci, P. M., de Stefano, V., et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia; a study of 150 families. Blood 92:2353, 1998.

76. Fijnheer, R., Paijmans, B., Verdonck, L. F., Nieuwenhuis, H. K., Roest, M., and Dekker, A. W. Factor V Leiden in central venous catheter-a ssociated thrombosis. Br. J. Haematol. 118:267-270, 2002.

77. Friedman, G. S., Meier-Kriesche, H. U., Kaplan, B., et al. Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis. Transplantation 27:1073-1078, 2001.

78. Vaandenbrouke, J. P., Koster, T., Briet, E., Reitsma, P. H., Bertina, R. M., Rosendaal, F. R., Increased risk of venous thrombosis in oral contraceptives users who are carriers of factor V Leiden mutation. Lancet 344:1453-1457, 1994.

79. Emmerich, J., Rosendaal, F. R., Catanneo, M. et al. Combined effect of factor F Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case control studies including 2310 cases and 3204 controls: study group for Pooled Analysis in Venous Thromboembolism. Thromb. Haemost. 86:809-816, 2001.

80. Koeleman, B. P. C., Reitsma, P. H., Allart, C. F., and Bertina, R. M. Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families. Blood 84:1031-1035, 1994.

81. Simioni, P., Tormene, D., Prandoni, P., et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 99:1938-1942, 2002.

82. Rosendaal, F. R., Doggern, C. J., Zivelin, A., et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb. Haemost. 79:706-708, 1998.

83. Girolami, A., Simioni, P., Scarano, L., and Carraro, G. Prothrombin and the prothrombin 20210 G to A polymorphism: their relationship with hypercoagulability and thrombosis. Blood Rev. 13:205-210, 1999.

84. Franco, R. F. Gene polymorphism of the haemostatic system and the risk of arterial thrombotic disease. Br. J. Haematol. 115:491-506,2001.

85. Brattstrom, L., Wilcken, D. E., Ohrvik, J., and Brudin, L. Common methylenetetrahydrofolate reductase gene mutation leads to hyper-homocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 98:2520-2526, 1998.

Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook

Post a comment